Scott A Tomlins
Overview
Explore the profile of Scott A Tomlins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
234
Citations
21516
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu M, Jagodinsky J, Callahan S, Minne R, Johnson D, Tomlins S, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400690.
PMID: 39983077
Purpose: Metastatic spread of non-small cell lung cancer (NSCLC) to the brain is a commonly occurring and challenging clinical problem, often resulting in patient mortality. Systemic therapies including immunotherapy have...
2.
Smith S, Melson J, Quillin J, Hiemenz M, Tomlins S, Wobker S
Am J Clin Pathol
. 2025 Jan;
PMID: 39838622
No abstract available.
3.
Singhal U, Nallandhighal S, Tosoian J, Hu K, Pham T, Stangl-Kremser J, et al.
Nat Commun
. 2024 May;
15(1):4341.
PMID: 38773085
Localized prostate cancer is frequently composed of multiple spatially distinct tumors with significant inter- and intra-tumoral molecular heterogeneity. This genomic diversity gives rise to many competing clones that may drive...
4.
Tosoian J, Zhang Y, Xiao L, Xie C, Samora N, Niknafs Y, et al.
JAMA Oncol
. 2024 Apr;
10(6):726-736.
PMID: 38635241
Importance: Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of...
5.
Bhambhani C, Kang Q, Hovelson D, Sandford E, Olesnavich M, Dermody S, et al.
JCI Insight
. 2024 Mar;
9(6).
PMID: 38516891
BACKGROUNDTransrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types.MethodsUsing whole-genome sequencing,...
6.
Bulen B, Khazanov N, Hovelson D, Lamb L, Matrana M, Burkard M, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1335-1349.
PMID: 37497337
Significance: This study confirms the utility of the integrative IRS biomarker for predicting anti-PD-L1/PD-1 benefit. IRS significantly improved upon currently available biomarkers, including PD-L1 IHC, TMB, and MSI status. Additional...
7.
Albrecht E, Carter J, Garbar V, Choudhary A, Tomlins S
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047742
In this study, we examined zinc trafficking in human umbilical vein endothelial cells (HUVEC) stimulated with (CA venom) snake venom. We utilized MTS cytotoxicity assays to monitor the cytotoxic range...
8.
Mehra R, Shah T, Liu C, Plouffe K, Wang X, Mannan R, et al.
Mod Pathol
. 2023 Feb;
36(6):100146.
PMID: 36828361
Prostate cancer is a heterogeneous disease with several well-recognized morphologic subtypes and histologic variants-subsets of which are enriched for or associated with specific genomic alterations. Herein, we report a cohort...
9.
Tomlins S, Khazanov N, Bulen B, Hovelson D, Shreve M, Lamb L, et al.
Commun Med (Lond)
. 2023 Feb;
3(1):14.
PMID: 36750617
Background: Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability, and tumor mutation burden (TMB) may improve benefit prediction. Methods:...
10.
Shore N, Cooperberg M, Tomlins S
JAMA Oncol
. 2022 Nov;
9(1):150-151.
PMID: 36385364
No abstract available.